PPCB

Propanc Biopharma, Inc. is a clinical stage biopharmaceutical company focused on developing cancer treatments for patients with pancreatic, ovarian, and colorectal cancers. The company is advancing a novel proteolytic proenzyme therapy aimed at inhibiting tumor growth and preventing metastasis. Propanc's business model involves conducting research and development to obtain regulatory approval for its therapies, leveraging a portfolio of intellectual property related to enzyme-based cancer treatments. The company collaborates with various research institutions and partners to enhance its product development and clinical testing efforts.